

Metastatic Colorectal Cancer Market - 2022-2030

<https://marketpublishers.com/r/M9713F604249EN.html>

Date: January 2026

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: M9713F604249EN

Abstracts

The Metastatic Colorectal Cancer Market was valued at US\$ 3.4 billion in 2022 and is anticipated to reach US\$ 4.8 billion by 2030, at a CAGR of 0.046 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Metastatic Colorectal Cancer Market.

This report delivers a comprehensive overview of the Metastatic Colorectal Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Metastatic Colorectal Cancer Market. The Metastatic Colorectal Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.

Metastatic Colorectal Cancer Market Scope:

By Treatment

Chemotherapy

Targeted Therapies

Immunotherapies

Others

By Drug Class

Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors

Anti-VEGF (Vascular Endothelial Growth Factor) Therapies

Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies

Immune Checkpoint Inhibitors

Others

By End-user

Hospitals

Cancer Centers

Ambulatory Surgical Centers

Others

Key Players

Amgen

EMD Serono

Eli Lilly

Genentech

Novartis AG

Pfizer Inc.

F. Hoffmann-La Roche Ltd

Sanofi

Suzhou Zelgen Biopharmaceuticals

Taiho Oncology

Major Highlights

This report delivers a comprehensive overview of the Metastatic Colorectal Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Metastatic Colorectal Cancer Market. The Metastatic Colorectal Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients

with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Treatment
- 3.2. Snippet by Drug Class
- 3.3. Snippet by End-user
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising FDA approval for Metastatic Colorectal Cancer Treatment
 - 4.1.2. Restraints
 - 4.1.2.1. Side effects associated with Metastatic Colorectal Cancer
 - 4.1.3. Opportunity
 - 4.1.3.1. Increasing research activities
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID-19
 - 6.1.2. Scenario During COVID-19

- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion

7. RUSSIA-UKRAINE WAR ANALYSIS

8. ARTIFICIAL INTELLIGENCE ANALYSIS

9. BY TREATMENT

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 9.1.2. Market Attractiveness Index, By Treatment
- 9.2. Chemotherapy*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Targeted Therapies
- 9.4. Immunotherapies
- 9.5. Others

10. BY DRUG CLASS

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.1.2. Market Attractiveness Index, By Drug Class
- 10.2. Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
- 10.4. Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
- 10.5. Immune Checkpoint Inhibitors
- 10.6. Others

11. BY END-USER

- 11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

- 11.2. Market Attractiveness Index, By End-user
- 11.3. Hospitals*
 - 11.3.1. Introduction
 - 11.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.4. Cancer Centers
- 11.5. Ambulatory Surgical Centers
- 11.6. Others

12. BY REGION

- 12.1. Introduction
 - 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 12.1.2. Market Attractiveness Index, By Region
- 12.2. North America
 - 12.2.1. Introduction
 - 12.2.2. Key Region-Specific Dynamics
 - 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 12.2.6.1. U.S.
 - 12.2.6.2. Canada
 - 12.2.6.3. Mexico
- 12.3. Europe
 - 12.3.1. Introduction
 - 12.3.2. Key Region-Specific Dynamics
 - 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 12.3.6.1. Germany
 - 12.3.6.2. U.K.
 - 12.3.6.3. France
 - 12.3.6.4. Italy
 - 12.3.6.5. Spain
 - 12.3.6.6. Rest of Europe
- 12.4. South America
 - 12.4.1. Introduction
 - 12.4.2. Key Region-Specific Dynamics

- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 12.4.6.1. Brazil
 - 12.4.6.2. Argentina
 - 12.4.6.3. Rest of South America

12.5. Asia-Pacific

- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 12.5.6.1. China
 - 12.5.6.2. India
 - 12.5.6.3. Japan
 - 12.5.6.4. Australia
 - 12.5.6.5. Rest of Asia-Pacific

12.6. Middle East and Africa

- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. COMPETITIVE LANDSCAPE

- 13.1. Competitive Scenario
- 13.2. Product Benchmarking
- 13.3. Company Share Analysis
- 13.4. Key Developments and Strategies

14. COMPANY PROFILES

- 14.1. Amgen*
 - 14.1.1. Company Overview
 - 14.1.2. Product Portfolio and Description
 - 14.1.3. Financial Overview

- 14.1.4. Key Developments
- 14.2. EMD Serono
- 14.3. Eli Lilly
- 14.4. Genentech
- 14.5. Novartis AG
- 14.6. Pfizer Inc.
- 14.7. F. Hoffmann-La Roche Ltd
- 14.8. Sanofi
- 14.9. Suzhou Zelgen Biopharmaceuticals
- 14.10. Taiho Oncology (*LIST NOT EXHAUSTIVE)

15. APPENDIX

- 15.1. About Us and Services
- 15.2. Contact Us

I would like to order

Product name: Metastatic Colorectal Cancer Market - 2022-2030

Product link: <https://marketpublishers.com/r/M9713F604249EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M9713F604249EN.html>